Both multinational corporations and small and medium-sized pharmaceutical companies benefit from ideal infrastructure and well-trained professionals here. The coexistence of small and large companies and the proximity to research institutions also contribute to creating an ideal climate for research and innovation.
The presence of highly qualified scientists and pharmaceutical talent from the world’s leading universities make a significant contribution towards developing new medicines. The framework conditions are also in place: the Swiss healthcare system supports the introduction of new medicines and, in doing so, offers companies access to a sophisticated test and sales market. In addition to Switzerland, international markets play a decisive role. Value added in the pharmaceutical industry has continued to increase over the last decade in Switzerland. Switzerland is by far the most important stock exchange for Life Sciences companies in Europe. Around a third of market capitalization on the SIX Swiss Exchange is attributable to Life Sciences companies.